Literature DB >> 77898

Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas.

R W Seiler, R H Greiner, A Zimmerman, H Markwalder.   

Abstract

Twenty consecutive patients with supratentorial Grade III and IV astrocytomas were treated with postoperative radiotherapy, and a simultaneous induction chemotherapy with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), procarbazine, bleomycin, and maintenance chemotherapy with CCNU. They were compared to 32 retrospective control patients selected similarly, who had received postoperative radiation therapy alone. The median survival time was 56 weeks for the combined treatment group, and 51 weeks for the control group. There was no statistical difference in survival in the two groups of patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 77898     DOI: 10.3171/jns.1978.48.6.0861

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Influence of type and extent of surgery on early results and survival time in glioblastoma multiforme.

Authors:  H G Höllerhage; M Zumkeller; M Becker; H Dietz
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

Review 2.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

3.  Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas.

Authors:  T Trojanowski; J Peszyński; K Turowski; S Kamiński; I Gościński; M Reinfus; T Krzyszkowski; M Pyrich; A Bielawski; C Leszczyk
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

4.  Combination chemotherapy (COMP protocol) and radiotherapy of anaplastic supratentorial gliomas.

Authors:  K Jellinger; P Kothbauer; D Volc; R Vollmer; R Weiss
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.